ThioTEPA

ThioTEPA

File:ThioTEPA.svg
Clinical data
Pregnancy category	AU: D US: D (Evidence of risk)
Routes of administration	IV, intracavitary, intravesical
ATC code	L01AC01 (WHO)
Legal status
Legal status	UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Metabolism	Hepatic (CYP2B6, CYP2C11)
Elimination half-life	2.4 hours 15-18 hours (metabolites)
Excretion	Renal
Identifiers
IUPAC name N,N ' N '-triethylenethiophosphoramide
CAS Number	52-24-4
PubChem CID	5453
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C6H12N3PS
Molar mass	189.219 g/mol

WikiDoc Resources for ThioTEPA
Articles
Most recent articles on ThioTEPA Most cited articles on ThioTEPA Review articles on ThioTEPA Articles on ThioTEPA in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on ThioTEPA Images of ThioTEPA Photos of ThioTEPA Podcasts & MP3s on ThioTEPA Videos on ThioTEPA
Evidence Based Medicine
Cochrane Collaboration on ThioTEPA Bandolier on ThioTEPA TRIP on ThioTEPA
Clinical Trials
Ongoing Trials on ThioTEPA at Clinical Trials.gov Trial results on ThioTEPA Clinical Trials on ThioTEPA at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on ThioTEPA NICE Guidance on ThioTEPA NHS PRODIGY Guidance FDA on ThioTEPA CDC on ThioTEPA
Books
Books on ThioTEPA
News
ThioTEPA in the news Be alerted to news on ThioTEPA News trends on ThioTEPA
Commentary
Blogs on ThioTEPA
Definitions
Definitions of ThioTEPA
Patient Resources / Community
Patient resources on ThioTEPA Discussion groups on ThioTEPA Patient Handouts on ThioTEPA Directions to Hospitals Treating ThioTEPA Risk calculators and risk factors for ThioTEPA
Healthcare Provider Resources
Symptoms of ThioTEPA Causes & Risk Factors for ThioTEPA Diagnostic studies for ThioTEPA Treatment of ThioTEPA
Continuing Medical Education (CME)
CME Programs on ThioTEPA
International
ThioTEPA en Espanol ThioTEPA en Francais
Business
ThioTEPA in the Marketplace Patents on ThioTEPA
Experimental / Informatics
List of terms related to ThioTEPA

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. Its main toxicity is myelosuppression.

References

• Sykes M; et al. (1953). "Clinical Studies of triethylenephosphoramide compounds with nitrogen mustard-like activity". Cancer. 6: 142–48.CS1 maint: Explicit use of et al. (link)
• Maanen MJ, Smeets CJ, Beijnen JH (2000). "Chemistry, pharmacology and pharmacokinetics of N,N',N" -triethylenethiophosphoramide (ThioTEPA)". Cancer Treat Rev. 26 (4): 257–68. PMID 10913381.CS1 maint: Multiple names: authors list (link)